{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-22-003344","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.536866+00:00","generated_at":"2026-06-21T05:27:19.126057+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"vTv Therapeutics appoints Steven Tuch as CFO, effective Dec 8, 2022","bullets":["Steven Tuch appointed CFO; base salary $450K, target bonus 40% of salary.","Tuch granted options for 500K shares vesting over 3 years; performance equity tied to $50M financing.","Severance: 9 months base salary if terminated without cause or resigns for good reason.","Tuch previously led Rallybio IPO ($92.7M) and 7 years at BMO Capital Markets.","Company preparing for Phase 3 trials of lead candidate TTP399 for type 1 diabetes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-22-003344","json":"https://secwatch.observer/filing/0000950142-22-003344.json","markdown":"https://secwatch.observer/filing/0000950142-22-003344.md","text":"https://secwatch.observer/filing/0000950142-22-003344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222003344/0000950142-22-003344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222003344/eh220309936_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:27:19.126057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0270987c97","claim":"Steven Tuch was appointed as Chief Financial Officer at vTv Therapeutics Inc..","evidence_excerpt":"the board of directors of the Company (the “Board”) has appointed Steven Tuch as Chief Financial Officer of the Company, effective as of December 8, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222003344/0000950142-22-003344-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}